In Vitro Activities of Rifamycin Derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and Recent Clinical Isolates of Chlamydia pneumoniae

ABI-1648 (rifalazil) is a semisynthetic rifamycin with potent bactericidal activity against intracellular respiratory bacteria, including Mycobacterium tuberculosis, and a long half-life (∼60 h) and thus can be administered once weekly. We therefore tested the in vitro activities of ABI-1648, its de...

Descripció completa

Dades bibliogràfiques

Publicat a:	Antimicrob Agents Chemother
Autors principals:	Roblin, Patricia M., Reznik, Tamara, Kutlin, Andrei, Hammerschlag, Margaret R.
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society for Microbiology (ASM) 2003
Matèries:	Susceptibility
Accés en línia:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC149300/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12604555/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.3.1135-1136.2003
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!